T1	p 90 153	chemo-na?ve patients with advanced non-small cell lung cancer .
T2	p 296 345	chemo-na?ve non-small cell lung cancer patients .
T3	p 354 420	Patients with chemo-na?ve stage IIIB/IV non-small cell lung cancer
T4	p 679 728	total of 80 patients were entered in this trial .
T5	p 1311 1348	advanced non-small cell lung cancer .
T6	i 59 86	of gemcitabine and oral S-1
T7	i 260 292	of gemcitabine combined with S-1
T8	i 488 491	S-1
T9	i 497 503	mg/m/d
T10	i 514 570	day ) from days 1 to 14 with gemcitabine ( 1000 mg/m/d )
T11	i 595 596	)
T12	i 1228 1262	combination of gemcitabine and S-1
T13	o 208 227	efficacy and safety
T14	o 778 803	rate . The response rates
T15	o 875 907	Median time to treatment failure
T16	o 958 984	Median time to progression
T17	o 1035 1055	Median survival time
T18	o 1128 1144	toxicity profile
T19	o 1418 1422	rate
T20	o 1427 1435	survival